893 related articles for article (PubMed ID: 36268520)
1. Management of Axial Spondyloarthritis - Insights into Upadacitinib.
Braun J; Kiltz U; Baraliakos X
Drug Des Devel Ther; 2022; 16():3609-3620. PubMed ID: 36268520
[TBL] [Abstract][Full Text] [Related]
2. JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials.
Keeling S; Maksymowych WP
Expert Rev Clin Immunol; 2021 Jul; 17(7):701-715. PubMed ID: 33944642
[TBL] [Abstract][Full Text] [Related]
3. Emerging therapies for the treatment of spondyloarthritides with focus on axial spondyloarthritis.
Braun J; Kiltz U; Baraliakos X
Expert Opin Biol Ther; 2023 Feb; 23(2):195-206. PubMed ID: 36511882
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis.
Webers C; Ortolan A; Sepriano A; Falzon L; Baraliakos X; Landewé RBM; Ramiro S; van der Heijde D; Nikiphorou E
Ann Rheum Dis; 2023 Jan; 82(1):130-141. PubMed ID: 36270657
[TBL] [Abstract][Full Text] [Related]
5. Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials.
Burmester GR; Stigler J; Rubbert-Roth A; Tanaka Y; Azevedo VF; Coombs D; Lagunes I; Lippe R; Wung P; Gensler LS
Rheumatol Ther; 2024 Jun; 11(3):737-753. PubMed ID: 38683479
[TBL] [Abstract][Full Text] [Related]
6. Upadacitinib for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA).
Fukui S; Kawaai S; Sawada H; Kishimoto M
Expert Rev Clin Immunol; 2024 Feb; 20(2):141-153. PubMed ID: 37955181
[TBL] [Abstract][Full Text] [Related]
7. JAK Inhibitors for Axial Spondyloarthritis: What does the Future Hold?
Akkoc N; Khan MA
Curr Rheumatol Rep; 2021 Apr; 23(6):34. PubMed ID: 33909185
[TBL] [Abstract][Full Text] [Related]
8. The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials.
Denis A; Sztejkowski C; Arnaud L; Becker G; Felten R
RMD Open; 2023 Jul; 9(3):. PubMed ID: 37507210
[TBL] [Abstract][Full Text] [Related]
9. Emerging treatment options for spondyloarthritis.
Torgutalp M; Poddubnyy D
Best Pract Res Clin Rheumatol; 2018 Jun; 32(3):472-484. PubMed ID: 31171316
[TBL] [Abstract][Full Text] [Related]
10. Comparison of patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) from a single rheumatology clinic in New Delhi.
Malaviya AN; Kalyani A; Rawat R; Gogia SB
Int J Rheum Dis; 2015 Sep; 18(7):736-41. PubMed ID: 26172961
[TBL] [Abstract][Full Text] [Related]
11. Treatment of axial spondyloarthritis: an update.
Danve A; Deodhar A
Nat Rev Rheumatol; 2022 Apr; 18(4):205-216. PubMed ID: 35273385
[TBL] [Abstract][Full Text] [Related]
12. Advances in pharmacotherapies for axial spondyloarthritis.
Toussirot E
Expert Opin Pharmacother; 2023; 24(13):1439-1448. PubMed ID: 37318776
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis.
Ortolan A; Webers C; Sepriano A; Falzon L; Baraliakos X; Landewé RB; Ramiro S; van der Heijde D; Nikiphorou E
Ann Rheum Dis; 2023 Jan; 82(1):142-152. PubMed ID: 36261247
[TBL] [Abstract][Full Text] [Related]
14. The term 'non-radiographic axial spondyloarthritis' is much more important to classify than to diagnose patients with axial spondyloarthritis.
Deodhar A; Strand V; Kay J; Braun J
Ann Rheum Dis; 2016 May; 75(5):791-4. PubMed ID: 26768406
[TBL] [Abstract][Full Text] [Related]
15. Effects of disease-modifying anti-rheumatic drugs on sacroiliac MRI score in axial spondyloarthritis: a systematic review and meta-analysis.
Hansmaennel A; Fakih O; Gerazime A; Prati C; Chouk M; Wendling D; Verhoeven F
Clin Rheumatol; 2024 Mar; 43(3):1045-1052. PubMed ID: 38158505
[TBL] [Abstract][Full Text] [Related]
16. The Future of Axial Spondyloathritis Treatment.
Maguire S; Sengupta R; O'Shea F
Rheum Dis Clin North Am; 2020 May; 46(2):357-365. PubMed ID: 32340707
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of Janus kinase inhibitors in axial spondyloarthritis.
Daoud A; Magrey MN
Indian J Dermatol Venereol Leprol; 2023 Jun; ():1-9. PubMed ID: 37436016
[TBL] [Abstract][Full Text] [Related]
18. Axial Spondyloarthritis: Evolving concepts regarding the disease's diagnosis and treatment.
Drosos AA; Venetsanopoulou AI; Voulgari PV
Eur J Intern Med; 2023 Nov; 117():21-27. PubMed ID: 37414646
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics and exposure-response analyses for efficacy and safety of upadacitinib in patients with axial spondyloarthritis.
Bhatnagar S; Eckert D; Stodtmann S; Song IH; Wung P; Liu W; Mohamed MF
Clin Transl Sci; 2024 Feb; 17(2):e13733. PubMed ID: 38344875
[TBL] [Abstract][Full Text] [Related]
20. New developments in ankylosing spondylitis-status in 2021.
Klavdianou K; Tsiami S; Baraliakos X
Rheumatology (Oxford); 2021 Dec; 60(Suppl 6):vi29-vi37. PubMed ID: 34951921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
